Humanigen — Corporate Update (December 2021)
27 slides from Humanigen's corporate update, Dec 2, 2021
Slide 1: Humanigen Discussion of The Lancet Respiratory Medicine Publications & Corporate Update
Humanigen Discussion of The Lancet Respiratory Medicine Publications & Corporate Update December 2, 2021
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this press release are forward - lo
Slide 3: Introduction
Dr. Cameron Durrant, Chairman & Chief Executive Officer Introduction
Slide 4: Lancet Respiratory Medicine Peer-Reviewed Paper Detailing Positive Results of LIVE-AIR Phase 3 study
4 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Respiratory Medicine Peer - Reviewed Paper Detailing Positive Results of LIVE - AIR Phase 3 study
Slide 5: Robust Clinical Pipeline
5 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Robust Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Hospitalized COVID - 19 3 Completed (520 patients) 24 US 11 Brazil Compa
Slide 6: The Lancet Respiratory Medicine Publications
Dr. Dale Chappell, Chief Scientific Officer The Lancet Respiratory Medicine Publications
Slide 7: Peer-Reviewed Paper Detailing Positive Results of LIVE-AIR Phase 3 study
7 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Peer - Reviewed Paper Detailing Positive Results of LIVE - AIR Phase 3 study
Slide 8: Independent Expert Commentary
8 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Independent Expert Commentary
Slide 9: Study Primary Endpoint Met: Kaplan-Meier Estimates for IMV and/or Death
9 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Study Primary Endpoint Met Kaplan - Meier Estimates For IMV and/or Death Failure to achieve survival without ventilation was defined as mortality or the require
Slide 10: The Lancet Respiratory Medicine Publication of LIVE-AIR
10 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry The Lancet Respiratory Medicine Publication of LIVE - AIR results in this peer - reviewed medical journal is a major achievement Findings might indicate the th
Slide 11: Associated independent comment makes supportive points about targeting GM-CSF
11 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry The Lancet Respiratory Medicine Associated independent comment makes supportive points about targeting GM - CSF and use of CRP as a biomarker to guide COVID -
Slide 12: LIVE-AIR and ACTIV-5 study comparison
12 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry LIVE - AIR ACTIV - 5 Recruitment sites 35 55 (Including 2 in S. Korea) Overall enrollment 520 up to 550 CRP<150 mg/L 351* 400* Inclusion criteria Adult, hospit
Slide 13: Regulatory Progress
Dr. Cameron Durrant, Chairman & Chief Executive Officer Regulatory Progress
Slide 14: Regulatory Progress Lenzilumab for COVID-19
14 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Regulatory Progress Lenzilumab for COVID - 19 1. Dec. 1, Lancet Respiratory Medicine publishes peer - reviewed paper and commentary on positive LIVE - AIR Phas
Slide 15: UK MHRA and Other Key Agencies
15 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry UK MHRA and Other Key Agencies Meetings held with Rapid C - 19 multi - agencies (MHRA, Therapeutics Task Force (TTF), NICE, NHSE, DHSC) Marketing Authorization
Slide 16: European Commission Ranks Lenzilumab as One of Ten Most Promising COVID-19 Treatments
16 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry European Commission Ranks Lenzilumab as One of Ten Most Promising COVID - 19 Treatments Selected for highest potential impact on the COVID - 19 pandemic Indepe
Slide 17: Regulatory Progress Lenzilumab for COVID-19
17 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Regulatory Progress Lenzilumab for COVID - 19 1. Dec. 1, Lancet Respiratory Medicine publishes peer - reviewed paper and commentary on positive LIVE - AIR Phas
Slide 18: Pipeline Progress
Dr. Adrian Kilcoyne, Chief Medical Officer Pipeline Progress
Slide 19: ACTIV-5/BET Big Effect Trial (BET-B) for the Treatment of COVID-19
19 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Study evaluating lenzilumab plus remdesivir vs. placebo plus remdesivir (NCT04583969) Over 400 compounds reviewed by NIH for inclusion in ACTIV protocols ACTIV
Slide 20: Robust Clinical Pipeline
20 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Robust Clinical Pipeline Indication Phase Status Centers Partners Lenzilumab LIVE - AIR Hospitalized COVID - 19 3 Completed (520 patients) 24 US 11 Brazil Comp
Slide 21: PREACH-M Trial Phase 2/3 for CMML
21 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry PREACH – M Trial Phase 2/3 for CMML PREACH – M Trial — First Patient Dosed October 2021 Partners Newly Diagnosed CMML Primary Endpoint 12 Months CR and PR Azac
Slide 22: aGvHD High Unmet Need; Lenzilumab RATinG Study Protocol
22 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry aGvHD High Unmet Need; Lenzilumab RATinG Study Protocol Allogeneic Stem Cell Transplant aGvHD Diagnosis Outcome prediction using “MAGIC” algorithm Standard of
Slide 23: SHIELD Phase 3 Study of Lenzilumab + Commercially Available CAR-T
23 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry SHIELD Phase 3 Study of Lenzilumab + Commercially Available CAR - T Phase 3 trial intended to address these barriers Non - Hodgkin lymphoma patients receiving
Slide 24: Closing Statement
Dr. Cameron Durrant, Chairman & Chief Executive Officer Closing Statement
Slide 25: Humanigen Corporate Statement
25 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently approved or authorized for use in any c ountry Humanigen Corporate Statement “Along with the scientific and medical communities, Humanigen supports the vaccination of individuals, despite the natural waning
Slide 26: Question & Answer Session
Dr. Cameron Durrant, Chairman & Chief Executive Officer Timothy Morris, COO & CFO Dr. Dale Chappell, CSO Dr. Adrian Kilcoyne, CMO Question & Answer Session
Slide 27: Thank You For Your Time
Humanigen Thank You For Your Time